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Introduction
Hemicrania Continua (HC) is a strictly unilateral continu-
ous headache that is exquisitely responsive to Indometacin
but some patients cannot tolerate this drug. Evidence for
other therapies is limited, often limited to single case
reports.
Aim
Onabotulinum Toxin A (BoNT-A) is licensed for use in
chronic migraine. Previous case reports on its use in HC
are limited to two patients. We present outcome data on
eight patients with HC treated with BoNT-A.
Methods
Eight patients with HC received BoNT-A treatment as per
the PRE-EMPT protocol for chronic migraine. Clinical
data was collected pre and post-treatment. Headache load
(defined as [severity (on the visual analogue score)] x
[duration] x [frequency] of headaches) of each patient was
calculated before and after treatment.
Results
The median number of treatments was 2 (range 1-8) and
the median number of BoNT-A units injected 165 (range
134-185). Six patients showed a headache load reduction
of over 50%. Median improvement in headache load post-
treatment was 88.5% (0-100%) with a significant difference
in headache load post-treatment (p=0.018). The median
duration of effect was 9.5 weeks (0-20 weeks). Five of six
responders were previously taking Indometacin on a daily
basis. All were able to switch to intermittent use of the
drug.
Conclusions
BoNT-A may be a useful treatment for HC where Indo-
metacin is not tolerated and adds another potential option
to the limited therapeutic arsenal currently available.
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